Oppenheimer Asset Management Inc. Has $1.14 Million Stock Position in Ascendis Pharma A/S (NASDAQ:ASND)

Oppenheimer Asset Management Inc. increased its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 10.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,622 shares of the biotechnology company’s stock after acquiring an additional 695 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Ascendis Pharma A/S were worth $1,138,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. SG Americas Securities LLC purchased a new stake in shares of Ascendis Pharma A/S in the first quarter worth approximately $288,000. ProShare Advisors LLC raised its position in Ascendis Pharma A/S by 9.9% in the 1st quarter. ProShare Advisors LLC now owns 4,025 shares of the biotechnology company’s stock valued at $608,000 after buying an additional 361 shares during the last quarter. Bessemer Group Inc. grew its stake in shares of Ascendis Pharma A/S by 61.0% in the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 332 shares in the last quarter. Nan Fung Group Holdings Ltd purchased a new stake in shares of Ascendis Pharma A/S in the first quarter valued at about $2,056,000. Finally, Capital International Investors lifted its position in shares of Ascendis Pharma A/S by 0.5% during the first quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock valued at $331,261,000 after purchasing an additional 10,044 shares in the last quarter.

Ascendis Pharma A/S Price Performance

Shares of ASND opened at $122.00 on Tuesday. The firm has a market cap of $7.40 billion, a PE ratio of -15.10 and a beta of 0.66. The stock’s fifty day moving average price is $132.40 and its two-hundred day moving average price is $132.47. Ascendis Pharma A/S has a 1 year low of $90.13 and a 1 year high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to analysts’ expectations of $94.74 million. Sell-side analysts anticipate that Ascendis Pharma A/S will post -7.3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ASND has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. reduced their price objective on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a research report on Wednesday, October 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a research report on Friday. Wedbush reissued an “outperform” rating and issued a $181.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday. Bank of America raised their target price on Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. Finally, TD Cowen cut their price target on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a report on Friday. One research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, Ascendis Pharma A/S has a consensus rating of “Moderate Buy” and an average target price of $191.77.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.